APA (7th ed.) Citation

P, G., D, R., E, F., F, d. l. C. V., D, M., V, B., . . . PM, B. (2026). Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting. Journal of geriatric oncology, 17(6), 103024. https://doi.org/10.1016/j.jgo.2026.103024

Chicago Style (17th ed.) Citation

P, Ghia, et al. "Patient-reported Outcomes in BRUIN CLL-321: A Randomized Phase 3 Trial Comparing Pirtobrutinib to Investigators Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma in the Post-cBTKi Setting." Journal of Geriatric Oncology 17, no. 6 (2026): 103024. https://doi.org/10.1016/j.jgo.2026.103024.

MLA (9th ed.) Citation

P, Ghia, et al. "Patient-reported Outcomes in BRUIN CLL-321: A Randomized Phase 3 Trial Comparing Pirtobrutinib to Investigators Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma in the Post-cBTKi Setting." Journal of Geriatric Oncology, vol. 17, no. 6, 2026, p. 103024, https://doi.org/10.1016/j.jgo.2026.103024.